231 related articles for article (PubMed ID: 12908569)
41. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
42. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
44. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
[TBL] [Abstract][Full Text] [Related]
45. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost.
Fechtner RD; Harasymowycz P; Nixon DR; Vold SD; Zaman F; Williams JM; Hollander DA
Clin Ophthalmol; 2011; 5():945-53. PubMed ID: 21792284
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma.
Park SW; Kim JM; Lee JW; Maglambayan J; Simonyi S; Park KH
Jpn J Ophthalmol; 2021 Mar; 65(2):295-305. PubMed ID: 33591471
[TBL] [Abstract][Full Text] [Related]
47. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
48. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
50. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.
Nordlund JR; Pasquale LR; Robin AL; Rudikoff MT; Ordman J; Chen KS; Walt J
Arch Ophthalmol; 1995 Jan; 113(1):77-83. PubMed ID: 7826297
[TBL] [Abstract][Full Text] [Related]
51. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
52. Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Öner V; Alakuş MF; Taş M; Türkyılmaz K; Işcan Y
J Ocul Pharmacol Ther; 2012 Dec; 28(6):576-80. PubMed ID: 22809091
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
54. The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure.
Seibold LK; DeWitt PE; Kroehl ME; Kahook MY
J Ocul Pharmacol Ther; 2017 Apr; 33(3):161-169. PubMed ID: 28129020
[TBL] [Abstract][Full Text] [Related]
55. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
56. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
[TBL] [Abstract][Full Text] [Related]
58. Effects of Switching from Timolol to Brimonidine in Prostaglandin Analog and Timolol Combination Therapy.
Aihara M; Adachi M; Hamada N; Honda N; Koseki N; Matsuo H; Miyata K; Otani S; Unoki K
J Ocul Pharmacol Ther; 2015 Oct; 31(8):482-6. PubMed ID: 26114331
[TBL] [Abstract][Full Text] [Related]
59. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
60. A comparison of 0.1% timolol eye gel and 0.5% timolol eye drop in patients with chronic angle-closure glaucoma.
Metheetrairut A; Leumsamran P; Rojananin S; Kitnarong N
J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S116-22. PubMed ID: 22696863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
